IL-12 Engineering & Application Development Services
Creative Biolabs provides comprehensive solutions to overcome the greatest hurdles in cytokine therapy: safety and specificity. Our engineered interleukin-12 (IL-12) constructs offer a dramatically wider therapeutic window by restricting activity to the tumor site while ensuring robust immune activation. This proprietary technology minimizes systemic toxicity, maximizing the anti-tumor potential of IL-12. We deliver next-generation IL-12 agonists that promise a new era of effective and well-tolerated cancer immunotherapy.
Background Featured Services What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Next-Generation IL-12 Engineering Strategies: Targeting Location and Specificity
Our proprietary platform utilizes modular protein engineering to create novel IL-12 constructs with improved safety and superior intratumoral activity. Pharmacokinetic (PK) is enhanced via PEGylation or Fc/albumin fusion for systemic half-life extension. Safety is maximized through spatially regulated fusions like collagen-binding domains (CBD) to achieve sustained, local tumor microenvironment (TME) retention, or immunocytokines targeting tumor-associated antigens (TAAs). Specificity is gained using bispecific IL-12 receptor agonists (e.g., sdAbs) to enable tailor-made biased agonism and conditionally active, split systems, ensuring anti-tumor benefits while mitigating systemic toxicity.
Our Featured Services
IL-12 Therapeutic Optimization
Creative Biolabs' IL-12 therapeutic optimization service engineers biased agonists and targeted fusions (e.g., CBD) to maximize anti-tumor activity precisely within the tumor microenvironment, ensuring superior safety and efficacy.
Learn More →
IL-12 Half-Life Extension Engineering
Unleash the full potential of IL-12 therapy while minimizing toxicity. Creative Biolabs' half-life extension engineering service uses PEGylation and Fc fusion to boost systemic exposure and reduce dosing frequency for safer, more effective immunotherapy.
Learn More →
Targeted IL-12 Delivery Engineering
Overcome IL-12's toxicity with Creative Biolabs' targeted IL-12 delivery engineering service. We create next-generation constructs using CBD fusion and biased agonism to restrict activity to the tumor site, ensuring superior safety and efficacy.
Learn More →
IL-12 Potency & Biased Signaling Engineering
Overcome IL-12's toxicity! Creative Biolabs' IL-12 potency & biased signaling engineering service designs next-generation cytokines that restrict activity to the TME. Achieve superior efficacy and a wider therapeutic window.
Learn More →
IL-12 Conditional Activation Development
Introducing the IL-12 conditional activation development service from Creative Biolabs. We eliminate systemic toxicity by engineering next-generation IL-12 agonists that are activated only at the tumor site, maximizing anti-tumor efficacy and safety.
Learn More →
IL-12 Combination Therapy Development
Maximize anti-tumor efficacy with Creative Biolabs' IL-12 combination therapy development service. We engineer next-generation IL-12 constructs for enhanced safety and synergistic activity with immune checkpoint inhibitors and cell therapies. Accelerate your IO breakthrough.
Learn More →
Key Deliverables and Problem-Solving Capabilities
Toxicity Mitigation
By fusing IL-12 with our CBD, we ensure the cytokine is trapped within the tumor's extracellular matrix (ECM), virtually eliminating systemic leakage and off-target liver toxicity (hepatotoxicity).
Precision Targeting
We develop split, conditionally active systems that function like a 'two-key' lock, only restoring full IL-12 activity when both components bind to two specific markers in the TME, ensuring unparalleled specificity.
Sustained, Localized Delivery
We develop cytokine factories—engineered cell carriers—that provide a continuous, high-dose source of IL-12 directly at the tumor site, promoting sustained T-cell recruitment without the systemic peaks associated with protein injection.
Enhanced Efficacy
Our biased agonism strategies selectively engage the IL-12 receptor (IL-12Rβ1 and IL-12Rβ2) on desired immune subsets, promoting the crucial differentiation of precursor exhausted T (Tpex) cells for durable, systemic anti-tumor immunity.
Contact Creative Biolabs today to schedule a confidential consultation with our scientific team and explore how our services can accelerate your program's path to the clinic.
Workflow
We offer a modular, collaborative process designed for seamless advancement from concept to IND-enabling studies. The complexity of the project, especially the choice of delivery platform, dictates the timeline.
Publication
To overcome the severe toxicity of IL-12 in cancer therapy, this study engineered bispecific antibody mimetics using single-domain antibodies (sdAbs) targeting the IL-12 receptor. These mimetics selectively activated the IL-12 pathway in pre-stimulated T cells—mimicking tumor-infiltrating lymphocytes—while sparing resting immune cells. By altering the sdAbs' spatial arrangement, this bias was enhanced. This work offers a tailored strategy to harness IL-12's anti-tumor benefits while decoupling them from systemic toxicity.
Fig.1 Preferential activation of stimulated T cells by an IL-12 mimicking sdAb. 1
Why Choose Us?
Creative Biolabs offers a unique advantage rooted in our pioneering scientific approach and two decades of biologics experience, allowing us to engineer safety and efficacy profiles. Our dual-focus advantage integrates targeted delivery (CBD-fusions, cytokine factories) and receptor modulation (biased agonism, split systems), dramatically increasing your clinical success probability. We possess Tpex cell expertise, validating our methodologies to recruit and differentiate these critical cells for robust, sustained anti-tumor responses. We provide an end-to-end solution, supporting seamless progression from initial molecular design through CMC and clinical-grade material production.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q:
How are your engineered IL-12 constructs better than older immunocytokines?
A:
Our approach goes beyond simple fusion. Critically, our delivery methods are engineered to facilitate the Tpex cell induction needed for durable, systemic anti-metastatic immunity, a key differentiator from first-generation agents.
Q:
Can you engineer IL-12 for my specific TAA?
A:
Absolutely. Our platform is highly modular. We customize fusion proteins, immunocytokines, and bispecific IL-12 receptor agonists to specifically recognize and bind to your TAA of choice, ensuring the therapeutic payload is delivered and activated only where needed.
Q:
What is the benefit of targeting Tpex cells?
A:
Tpex cells are crucial for long-term anti-tumor immunity. Our localized IL-12 delivery is proven to efficiently induce Tpex cell recruitment, leading to the systemic (abscopal) elimination of both primary and metastatic tumors.
Customer Review
-
Reduced Systemic Toxicity
Using Creative Biolabs' CBD-fusion IL-12 in our research has significantly facilitated the drug safety profile, allowing us to test doses previously deemed too toxic. Their data on ALT leakage was superior to published industry benchmarks. - Dr. L**t Chen
-
Precise Targeted Activation
Using Creative Biolabs' service in our research has significantly improved dual-antigen targeting, providing the high confidence needed to move forward with a double-positive cancer indication, far exceeding the specificity of single-antibody conjugates. - J. L**s Ramirez
Related Services
To complement your IL-12 program, Creative Biolabs offers several synergistic services:
Next Immunocytokine Engineering Development Service
Creative Biolabs specializes in immunocytokine engineering development services, fusing cytokines with targeting proteins (like antibodies) to modulate localization, mitigate systemic toxicity, and enhance therapeutic efficacy within the TME.
Learn More →
Next CAR-T Therapy Development
Creative Biolabs is committed to supporting cell and gene therapy development, providing data, expertise, and comprehensive services to solve unique challenges in manufacturing and non-clinical research.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs is your single-source partner, combining advanced protein engineering with clinically translatable delivery platforms to accelerate your next-generation IL-12 therapeutic.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Lipinski, Britta, et al. "Taming interleukin‐12: Engineering of bispecific antibody‐based IL‐12 mimetics with biased agonism capacities." Protein Science 34.3 (2025): e70072. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1002/pro.70072
